drugset / Trial / NCT01395147

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

NCT01395147

Phase 3 Completed 119 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Lu AA21004 in participants with major depressive disorder after completion of an 8-week double-blind treatment period in a preceding study (Lu AA21004/CCT-003; NCT01355081).

Timeline

Start
2011-07
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral